Moderna Stock News

Privia Health Group <> has partnered with Javara to advance a phase 2/3 study for mRNA-1345, an investigational vaccine candidate developed by Moderna (MRNA) for the…

The biotech currently only owns manufacturing facilities in the U.S.

Stocks started off lower in Monday''s premarket but were nearing a break-even start to regular trading.

US mRNA pioneer in late stage discussions with government over move that would boost post-Brexit life sciences strategy

You might remember that Moderna CEO Stephane Bancel was recently pushing for another COVID-19 booster shot only weeks ago. Now it appears hes running for the hills. Social media is buzzing with rumors that Bancel has deleted his personal Twitter and dumped a ton of his stock held in the company he leads. It turns [] The post ALERT: Moderna CEO Deletes Twitter, Dump Some of His Stock appeared first on Analyzing America .

Days after Pfizer admitted a safety audit could wipe billions off their stock market valuation, Moderna CEO Stéphane Bancel was dumped hundreds of millions of dollars in stock and deleted his Twitter account. Nothing to [] The post Moderna CEO Just Dumped $400 Million in Stock and Deleted His Twitter Account appeared first on News Punch .

Tedros Adhanom Ghebreyesus was speaking during a visit to Afrigen Biologics and Vaccines, which has produced the first mRNA Covid vaccine made in Africa using Moderna''s sequence

Tedros Adhanom Ghebreyesus was speaking during a visit to Afrigen Biologics and Vaccines, which has produced the first mRNA Covid vaccine made in Africa using Moderna''s sequence

Pfizer, Moderna booster efficacy wanes significantly by fourth month, finds US study

The efficacy of third doses of the Pfizer and Moderna mRNA vaccines wanes substantially by the fourth month after administration, a new study by the US Centers of Disease Control and Prevention (CDC)…

mRNA COVID-19 vaccine boosters from Pfizer/BioNTech and Moderna become less effective after four months, but still provide significant protection against hospitalization.

The European Medicines Agency''s safety committee is reviewing reports of heavy menstrual bleeding and absence of menstruation after COVID-19 vaccines from Pfizer Inc (NYSE: PFE ) / BioNTech SE (NASDAQ: BNTX ), and Moderna Inc (NASDAQ: MRNA ). The assessment was because of reports of menstrual disorders after receiving both vaccines, and it was not yet clear … Full story available on Benzinga.com

A European Medicines Agency safety committee is investigating cases of menstrual disorders seen with mRNA COVID-19 vaccines made by Pfizer /BioNTech and Moderna.

The European Medicines Agency''s safety committee said on Friday it was reviewing reports of heavy menstrual bleeding and absence of menstruation with COVID-19 vaccines from Pfizer/BioNTech and Moderna .